Evidence map›Paper›PMID 42253400›Full record

ReviewPathogens & immunity2026

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.

Simone Tunesi, Graham Bothamley, Gunar Günther, Yousra Kherabi, Liga Kuksa, Berit Lange, Christoph Lange, Natalie Lorent, Francesca Saluzzo, Martina Sester and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pathogens & immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Simone TunesiInfectious Diseases Unit, AOU SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
Graham BothamleyHomerton University Hospital, London, United Kingdom.
Gunar GüntherDepartment of Pulmonology, Allergology and Clinical Immunology, Inselspital Bern, Bern University Hospital, Bern, Switzerland.
Yousra KherabiInfectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
Liga KuksaTuberculosis and Lung Disease clinic, Riga East University hospital, Riga, Latvia.
Berit LangeDepartment of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Christoph LangeInfectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Natalie LorentDepartment of Respiratory Diseases, University Hospital Leuven, Leuven, Belgium.
Francesca SaluzzoIRCCS San Raffaele Scientific Institute, Milan, Italy.
Martina SesterDepartment of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
Xenia Emilie Sinding IversenInternational Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark.
Marc TebrueggeDepartment of Child and Adolescent Medicine & Austrian National Reference Centre for Childhood Tuberculosis, Klinik Ottakring, Vienna Healthcare Group, Vienna, Austria.
Conor TweedMRC Clinical Trials Unit, University College London, London, United Kingdom.
Anca VasiliuInfectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Lorenzo GuglielmettiDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Tuberculosis Network European Trials group (TBnet)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis (TB) remains a major cause of morbidity and mortality worldwide, while infections from non-tuberculous mycobacteria (NTM) represent a growing public health threat. In its 20 Methods: We conducted a non-systematic review of articles published in 2025, with a strong emphasis on research with current or potential impact on clinical practice. We also selected the most impactful papers regarding the management of adult TB, pediatric TB, and NTM infections. Results: Members of the TBnet Steering Committee summarize the main advances in their areas of interest, including epidemiology, pathogenesis, prevention, diagnosis, treatment, pediatric TB, and NTM infections. We also include a summary of future research priorities. Conclusions: The year 2025 presented many exciting advancements in almost all fields of mycobacterial science. This article provides an expert-based, clinically orientated summary of the main new findings in the TB and NTM fields and aims to provide an updated overview of the state of the art in those areas.

Indexed as

NTMpediatric TBTBTBnet

Identifiers

PMID42253400
PMCPMC13242177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.